Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Phase II VICTOR-E1 clinical study results reported

Phase II VICTOR-E1 clinical study results reported

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Clinton Foundation reaches deal with Matrix, Pfizer to cut prices for second-line Arvs, TB drug

Clinton Foundation reaches deal with Matrix, Pfizer to cut prices for second-line Arvs, TB drug

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

Bill Clinton, Pfizer, and Mylan announce new agreements to lower prices of antiretrovirals for HIV/AIDS in the developing world

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Early retroviral use best for AIDS patients with serious complications

Early retroviral use best for AIDS patients with serious complications

Early use of antiretroviral treatment improves survival rate of HIV patients

Early use of antiretroviral treatment improves survival rate of HIV patients

Mylan's Matrix receives WHO approval for generic Lopinavir/Ritonavir tablets

Mylan's Matrix receives WHO approval for generic Lopinavir/Ritonavir tablets

AIDS advocates tell WHO: Stop harmful single-dose treatment for expectant mothers and infants

AIDS advocates tell WHO: Stop harmful single-dose treatment for expectant mothers and infants

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

Abbott Labs agrees to settle lawsuit over antiretroviral Norvir pricing

Abbott Labs agrees to settle lawsuit over antiretroviral Norvir pricing

Gilead initiates phase III trial of Elvitegravir

Gilead initiates phase III trial of Elvitegravir

Clinton Foundation, UNITAID announce new antiretroviral discounts

Clinton Foundation, UNITAID announce new antiretroviral discounts

Pharmacies, drug wholesaler file lawsuit against Abbott over price of antiretroviral Norvir

Pharmacies, drug wholesaler file lawsuit against Abbott over price of antiretroviral Norvir

Etravirine reduces HIV viral loads when taken with Prezista

Etravirine reduces HIV viral loads when taken with Prezista

Darunavir-ritonavir shows benefits for patients with HIV

Darunavir-ritonavir shows benefits for patients with HIV

WHO welcomes decision by Abbott Labs to reduce price of lopinavir/ritonavir

WHO welcomes decision by Abbott Labs to reduce price of lopinavir/ritonavir

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott agrees with WHO to expand access to lopinavir / ritonavir